AR and prostate cancer: In prostate cancer (PC), given that androgen receptor splice variant 7 (AR‐V7) functions as a very promising biomarker and patients with CTCs AR‐V7(+) metastatic castration‐resistant prostate cancer (CRPC) had a very poor outcome, Armstrong et al.55